1
|
Waschbusch M, Rodriguez L, Brueckner A, Lee KJ, Li X, Mokliatchouk O, Tremmel L, Yuan SS. Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions. Pharmaceut Med 2022; 36:201-213. [PMID: 35780471 DOI: 10.1007/s40290-022-00435-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2022] [Indexed: 11/24/2022]
Abstract
In the last decade there has been a significant increase in the literature discussing the use of benefit-risk methods in medical product (including devices) development. Government agencies, medical product industry groups, academia, and collaborative consortia have extensively discussed the advantages of structured benefit-risk assessments. However, the abundance of information has not resulted in a consistent way to utilize these findings in medical product development. Guidelines and papers on methods, even though well structured, have not led to a firm consensus on a clear and consistent approach. This paper summarizes the global landscape of benefit-risk considerations for product- or program-level decisions from available literature and regulatory guidance, providing the perspectives of three stakeholder groups-regulators, collaborative groups and consortia, and patients. The paper identifies key themes, potential impact on benefit-risk assessments, and significant future trends.
Collapse
Affiliation(s)
- Max Waschbusch
- Global Clinical Safety and Pharmacovigilance, CSL Behring, King of Prussia, PA, USA.
| | - Lisa Rodriguez
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | | | - Kerry Jo Lee
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - Xuefeng Li
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | | | - Lothar Tremmel
- Quantitative Sciences and Reporting, CSL Behring, King of Prussia, PA, USA
| | - Shuai S Yuan
- Oncology Statistics, GlaxoSmithKline Plc, Upper Province, PA, USA
| |
Collapse
|
2
|
Smith MY, Benattia I, Strauss C, Bloss L, Jiang Q. Structured Benefit-Risk Assessment Across the Product Lifecycle: Practical Considerations. Ther Innov Regul Sci 2017; 51:501-508. [DOI: 10.1177/2168479017696272] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|